Update on Global Heart Failure Program
Filed with ASX · · 3 pages · English
Earlier from Mesoblast
- Suspension from Official Quotation
- Mesoblast Receives $6.2m From Aus Govt For R&D
- Mesoblast Provides Q3 Financial Results and Corporate Update
- Mesoblast Cells Show Disease Modifying Effects on Knee OA
- MSB partner JCR files for product approval
Later from Mesoblast
- Update on Heart Failure Trial and Funding of Operations
- MSB Back Pain Results Presented, Receive Best Science Award
- Mesoblast P2 Results Show Dose-Related Improvements In RA
- MSB Strengthens US Patent Portfolio For Rheumatic Diseases
- Preliminary Final Report (Including Appendix 4E)
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast